

Product Datasheet

Order: order@ebiocell.com

TEL: (540)808-3925

Supprt: tech@ebiocell.com
Web: www.ebiocell.com

Phospho-EGFR (Tyr1092) Rabbit Polyclonal Antibody

Catalog #: EAB10486

Host/Isotype	Clonality	Applications	MW (kDa)	Reactivity
Rabbit IgG	Polyclonal	WB, IHC-P, IF, ELISA	134	Human, Mouse, Rat

Applications Dilutions

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

WB(Western Blotting)1:500-2000IHC-P(Immunohistochemistry-Paraffin)1:50-300IF(Immunofluorescence)1:50-300ELISA(Enzyme-linked Immunosorbent Assay)1:5000-20000

Product Information

Conjugate Unconjugate

Specificity

Phospho-EGFR (Tyr1092) Rabbit Polyclonal Antibody detects endogenous levels of EGFR only

when phosphorylated at Tyr1092.

Purification Affinity purification

Concentration1mg/mlFormatLiquid

Formulation In PBS, pH 7.4, Containing 0.02% sodium azide, 0.5% BSA and 50% Glycerol

Shipping Gel Pack

Storage Storag

Aliquots may be stored at +4°C for 1-2 weeks

 UniProt ID
 P00533

 Entrez-Gene Id
 1956

Product Description

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Exons in the EGFR gene product are frequently either deleted or duplicated to produce deletion mutants (DM) or tandem duplication mutants (TDM), respectively, which are detected at various molecular weights. EGFR binds several ligands, including epidermal growth factor (EGF), transforming growth factor α (TGFα), Amphiregulin and heparin binding-EGF (HB-EGF). Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target.